You have full text access to this OnlineOpen article

Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer

  1. Avishay Sella1,
  2. Cora Sternberg1,
  3. Svetlana Kovel1,
  4. Nirit Yarom1,
  5. Iwona Skoneczna2

Article first published online: 8 JUN 2007

DOI: 10.1111/j.1464-410X.2007.07037.x

Issue

BJU International

BJU International

Volume 100, Issue 3, pages 533–535, September 2007

Additional Information

How to Cite

Sella, A., Sternberg, C., Kovel, S., Yarom, N. and Skoneczna, I. (2007), Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. BJU International, 100: 533–535. doi: 10.1111/j.1464-410X.2007.07037.x

Author Information

  1. 1

    Department of Oncology, Assaf Harofeh Medical Center, Zerifin (affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel), Department of Oncology, San Camillo and Forlanini Hospitals, Rome, Italy, and

  2. 2

    Department of Oncology, M. Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

*Avishay Sella, Department of Oncology, Assaf Harofeh Medical Center, Zerifin 70300, Israel. e-mail: avisella@netvision.net.il

Publication History

  1. Issue published online: 31 JUL 2007
  2. Article first published online: 8 JUN 2007
  3. Accepted for publication 16 March 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (94K)

Keywords:

  • PSA doubling time;
  • androgen-independent prostate cancer;
  • docetaxel

OBJECTIVE

To assess the clinical pattern of progression and prostate-specific antigen doubling time (PSA-DT) after exposure to docetaxel-based chemotherapy in patients with androgen-independent prostate cancer (AIPC).

PATIENTS AND METHODS

Fifty-five patients received docetaxel-based chemotherapy; data were collected retrospectively from three different departments. Progression was known in 44 (79%) and the PSA-DT was available in 33 patients.

RESULTS

Of the 29 patients with soft-tissue and soft-tissue plus bone metastases, 22 (76%) developed soft-tissue progression. Among the 35 patients with bone and bone plus soft-tissue metastases, 27 (77%) had osseous progression. There was no difference between the PSA-DT at progression before and after docetaxel-based therapy (mean 3.1 vs 2.7 months, P = 0.592, Student’s t-test.). However, the median (range) PSA-DT at progression after docetaxel-based therapy was 0.84 (0.3–4) months in patients with a PSA response, significantly shorter than the median of 3.1 (0.3–12) months of patients with no biochemical response (P = 0.002, Student’s t-test). The PSA-DT dynamics at progression had no effect on survival (P = 0.63, log-rank test).

CONCLUSION

The pattern of progression after docetaxel-based chemotherapy is predominantly osseous in patient with bone metastases and mostly soft-tissue in those with soft-tissue disease. Progression after docetaxel-based chemotherapy in AIPC does not modify the PSA-DT before docetaxel. Evaluation of a larger population is needed to assess the clinical relevance of PSA dynamics after docetaxel therapy.

View Full Article (HTML) Get PDF (94K)